DANVERS, Mass.--(BUSINESS WIRE)--April 12, 2006--Cell Signaling Technology, Inc. (CST) announced today a third agreement with AstraZeneca under which it will continue to perform CST’s PhosphoScan® technology to identify phosphorylation profiles and prospective biomarkers of kinase targeted lead compounds. CST’s PhosphoScan® proteomics technology is a patent-pending strategy that enables the discovery of drug target phospho-profiles (Phospho-Signatures(TM)) in cells and disease tissues. The PhosphoScan® technology involves immunoaffinity purification and mass spectroscopy and was described in the journal Nature Biotechnology (Rush J. et al, Nat. Biotechnol. 23, 94-101 (2005)). The Phospho-Signatures(TM) discovered using PhosphoScan® may enable biomarker assays for target validation and therapeutic kinase inhibitor clinical development.
